Ascletis Pharma at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
Ascletis Pharma brings 2 presentations to ObesityWeek 2026 in National Harbor. Its sessions present preclinical work on obesity drug candidates. One studies the oral small molecule GIPR agonist ASC48 in vitro and in vivo, and another reports a longer half-life for ASC37 than retatrutide in nonhuman primates and marked weight loss in DIO mice.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Ascletis Pharma Hangzhou, China | |
Biotech developing oral and long-acting peptide candidates for obesity, including ASC37 and ASC48. | Poster Sat Nov 14 7:30pm–8:30pm ASC37 Showed 6-Fold Longer Half-Life Than Retatrutide in NHP and Marked Weight Loss in DIO Mice Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Oral Small Molecule GIPR Agonist ASC48 for Obesity: In Vitro and In Vivo Studies Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology |
Find decision makers at Ascletis Pharma
Tell us what you sell and we’ll find the people at Ascletis Pharma most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction